Rhythm Pharmaceuticals (RYTM) Cost of Revenue (2021 - 2026)

Rhythm Pharmaceuticals (RYTM) has reported Cost of Revenue for 6 consecutive years, with $7.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cost of Revenue rose 96.19% year-over-year to $7.2 million; the TTM figure through Mar 2026 stood at $23.0 million (up 61.86% YoY), while the FY2025 annual figure was $19.5 million, up 45.81% from the prior year.
• Cost of Revenue improved to $7.2 million in Q1 2026 per RYTM's latest filing, from $4.8 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $7.2 million in Q1 2026 and bottomed at $230000.0 in Q1 2022.
• Historically, Cost of Revenue has averaged $3.0 million across 5 years, with a median of $2.9 million in 2024.
• Annual changes were most pronounced in 2022 — Cost of Revenue jumped 5650.0% — and 2024, when it advanced 17.14%.
• Rhythm Pharmaceuticals' Cost of Revenue stood at $1.0 million in 2022, then soared by 214.49% to $3.2 million in 2023, then grew by 17.14% to $3.8 million in 2024, then increased by 26.8% to $4.8 million in 2025, then soared by 49.04% to $7.2 million in 2026.
• Business Quant data shows RYTM's Cost of Revenue at $7.2 million in Q1 2026, $4.8 million in Q4 2025, and $5.5 million in Q3 2025.